publication . Article . 2011

Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.

Eric M. Reiman; Jessica B.S. Langbaum; Adam S. Fleisher; Richard J. Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T. Quiroz; Kenneth S. Kosik; Francisco Lopera; Pierre N. Tariot;
  • Published: 04 Oct 2011
  • Publisher: IOS Press
Abstract
There is an urgent need to find effective presymptomatic Alzheimer's disease (AD) treatments that reduce the risk of AD symptoms or prevent them completely. It currently takes too many healthy people, too much money and too many years to evaluate the range of promising presymptomatic treatments using clinical endpoints. We have used brain imaging and other measurements to track some of the earliest changes associated with the predisposition to AD. We have proposed the Alzheimer's Prevention Initiative (API) to evaluate investigational amyloid-modifying treatments in healthy people who, based on their age and genetic background, are at the highest imminent risk o...
Subjects
free text keywords: Clinical Psychology, Geriatrics and Gerontology, Psychiatry and Mental health, General Medicine, Disease, Apolipoprotein E, Alzheimer's disease, medicine.disease, medicine, Early-onset Alzheimer's disease, Internal medicine, medicine.medical_specialty, Pathology, Pediatrics, Clinical trial, Presenilin, Biomarker (medicine), business.industry, business, Clinical endpoint, Endocrinology
Related Organizations
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2011

Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.

Eric M. Reiman; Jessica B.S. Langbaum; Adam S. Fleisher; Richard J. Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T. Quiroz; Kenneth S. Kosik; Francisco Lopera; Pierre N. Tariot;